Bringing the fundamentals into focus…
Back to Neumora Therapeutics, Inc.
How Neumora Therapeutics, Inc. stacks up
NMRA · against 100 other Healthcare companies of similar size
Valuation
75/ 100
Above the middle of the pack.
Ranked #28 of 101 · scores higher than 72% of peers
Bars: peers in each 10-point band of the valuation score7 peers with a valuation score of 70–79, including NMRA · Click a bar to see the companies
Why valuation scores 75?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- lower earnings for the price paid: weaker than 99% of peers. Earnings yield: 243.4% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -288.4% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -168.3% vs peer median 0.0%
Metric by metric
Position: dot = NMRA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | NMRA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 85 reported | -189.1% | -13.3% | 2% | 30% | |
| EBITDA yieldHigher is better · 109 reported | -471.8% | -3.4% | 9% | 50% | |
| Free cash flow yieldHigher is better · 76 reported | -168.3% | -15.0% | 1% | 20% | |
| Book yieldHigher is better · 90 reported | 41.7% | 73.3% | 33% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around NMRA| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 24 | 131M CAD (≈$96M) | 82 | 40 | |
| 25 | 3.0B THB (≈$83M) | 79 | 52 | |
| 26 | 4.2B TWD (≈$129M) | 77 | 57 | |
| 26 | 13.2B JPY (≈$90M) | 77 | 64 | |
| 28 | 107M USD | 75 | 31 | |
| 28 | 540M ILS (≈$146M) | 75 | 49 | |
| 30 | 166.9B KRW (≈$120M) | 74 | 48 | |
| 30 | 30.4B JPY (≈$206M) | 74 | 57 | |
| 32 | 105.8B KRW (≈$76M) | 68 | 41 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score